CTGL
Citrine Global Corp.0.1915
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
236.35MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
SkyTech Orion Global posted a narrower operating loss of $377K in Q3 ended September 30, 2025, up 44% y/y from $263K (derived), while nine-month operating loss improved to $832K from $930K y/y (derived). No revenue yet, but ramped R&D spend to $146K in Q3 on drone tech pivot, offset by lower G&A from cut share-based comp. Net loss held steady at $386K quarterly despite $432K YTD hit from Nanomedic impairment; financing costs dropped sharply post-convertible note conversions. Cash ticked to $7K, propped by $342K financing inflows against $730K total debt including related-party short-term loans backed by personal guarantees and Yeruham land lien; $222K op cash burn. Secured NIS 12.5M (~$3.4M) Israeli grant for defense drone center. Ongoing Israel war disrupts operations.
8-K
CEO letter on developments
8-K
Appoints Lior Asher to board
Citrine Global appointed Lior Asher to its Board on October 5, 2025. Asher brings over 20 years in high-tech investments, directing Skytech Orion Israel and Citrine's 69.5%-owned SkyTech Orion Ltd. subsidiary, plus leading Or HaTzvi Group's engineering and defense solutions. New director. Board gains deep industry ties.
10-K
FY2023 results
Citrine Global posted FY2023 net loss of $3.1M, up from $2.6M in 2022, on zero revenue as operations ramp. R&D dipped to $96K while G&A jumped 18% to $2.2M from share-based comp; financing expenses rose to $807K on convertible note tweaks. Cash dwindled to $7K with $2.5M working capital deficit, offset by $182K drawn on related-party credit facility secured by Yerucham land. No quarterly breakdowns disclosed. Ongoing Israeli war disrupts execution. Debt overhang persists.
10-Q
Q1 FY2024 results
Citrine Global narrowed its Q1 operating loss to $403K from $517K y/y, thanks to zero R&D spend and steady G&A outlays, while financing flipped to $151K net gain from $335K loss on lower convertible note costs and $185K IBOT option fair value gain. Net loss eased to $252K from $852K, matching basic loss per share of $0.00 on ~999M weighted shares. Cash dwindled to $4K amid $45K operating burn, offset by $42K net financing inflows; short-term loans hit $237K with $2.2M related-party payables and $2.2M convertibles. Credit facility with S.R. Accord remains available, backed by Yerucham land lien. Ongoing Israeli war disrupts operations.
IPO
Employees
Sector
Industry
BDPT
Bioadaptives, Inc.
0.03+0.00
CFOO
CHINA FOODS HOLDINGS LTD
0.66+0.00
FTLF
FitLife Brands, Inc.
18.10-0.28
GLUC
Glucose Health, Inc.
0.14+0.00
HAIN
The Hain Celestial Group, Inc.
1.11-0.06
HLF
Herbalife Ltd.
14.45-0.45
NATR
Nature's Sunshine Products, Inc
22.38-0.85
NPRFF
NEPRA FOODS INC.
0.10+0.00
PSYCF
Psyched Wellness Ltd.
0.01-0.00
TOBAF
TAAT Global Alternatives Inc.
0.04+0.00